Abstract
Nearly two decades ago, diabetes mellitus (DM) and cardiovascular disease (CVD) emerged as major global health threats, with research interest steadily increasing. Despite ongoing in-depth studies in the DM+CVD field, a systematic analysis of overall development trends and future hotspots remains lacking. This study employs bibliometric methods, utilizing CiteSpace and VOSviewer software to analyze and visualize 5,505 DM+CVD-related publications from 2005 to May 2024. The findings reveal a rapid growth trend in the field, with publications peaking at 751 in 2022, and the United States and China as major contributing countries. Keyword analysis identifies research hotspots including oxidative stress, insulin resistance, and heart failure. Highly cited literature analysis shows that the relationship between DM+CVD and obesity, disease mechanisms, treatment strategies, lifestyle interventions, and novel drugs are primary research themes. Analysis of highly cited literature from the past three years indicates that the application of SGLT2 inhibitors and GLP-1 receptor agonists, the association between metabolic abnormalities and DM+CVD, precise management of heart failure and cardiomyopathy, and in-depth epidemiological studies are current and future research priorities. This study not only reveals research hotspots and development trends in the DM+CVD field but also provides important references for optimizing research resource allocation and promoting multidisciplinary collaboration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research did not require IRB approval or exemption as it did not involve human subjects, animal experiments, or other ethical concerns that would necessitate review by an ethics committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Jingjin Wang, Yinxia SU and Yukai Li takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
E-mail address of all authors: JW:1099337027{at}qq.com; TS:644580772{at}qq.com; Yl:16699195071{at}stu.xjmu.edu.cn; YS:yinxia_su{at}xjmu.edu.cn; YL:XjLyk11{at}tomm.com.
Funding: This work was supported by the Special Project for Innovation Environment (Talent, Base) Construction in Xinjiang Uygur Autonomous Region and the HeTian Prefecture Science and Technology Research and Development Program Project (NO.2022D01A256 and NO.202314).
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
